At AMCP Nexus 2026, Carmen Witsken, PharmD, discusses high upfront cell and gene therapy costs and the case for a national risk pool.
Carmen G. Witsken, PharmD
Advertisement
Carmen G. Witsken, PharmD, is the senior manager of pharmacy policy at the Alliance of Community Health Plans.
Articles by Carmen G. Witsken, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Occasional Cannabis Use Linked to 40% Higher Odds of Stroke
2
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
3
GLP-1 Use Tied to Lower Diabetes, CV Risk vs Metformin in Prediabetes
4
Invivyd Unveils Measles Antibody Candidate VMS063 at IDWeek 2026
5